Edwards Lifesciences Corporation Operating Lease, Right-of-Use Asset, Amortization Expense
Edwards Lifesciences Corporation (EW) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $13.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-04
- Edwards Lifesciences Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $6.60M, a 3.13% increase year-over-year.
- Edwards Lifesciences Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $6.50M, a 6.56% increase year-over-year.
- Edwards Lifesciences Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $6.60M, a 6.45% increase year-over-year.
- Edwards Lifesciences Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $6.80M, a 4.62% increase year-over-year.
- Edwards Lifesciences Corporation operating lease, right-of-use asset, amortization expense for fiscal 2025 was $25.90M, a 6.83% decline from fiscal 2024.
- Edwards Lifesciences Corporation operating lease, right-of-use asset, amortization expense for fiscal 2024 was $27.80M, a 1.42% decline from fiscal 2023.
- Edwards Lifesciences Corporation operating lease, right-of-use asset, amortization expense for fiscal 2023 was $28.20M, a 3.68% increase from fiscal 2022.
- Edwards Lifesciences Corporation operating lease, right-of-use asset, amortization expense for fiscal 2022 was $27.20M, a 4.56% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $13.10M 10-Q · filed 2026-08-04 | $19.70M derived: sum of 3 quarters · filed 2026-08-04 | $26.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $6.50M 10-Q · filed 2026-05-06 | $13.10M derived: sum of 2 quarters · filed 2026-05-06 | $19.90M derived: sum of 3 quarters · filed 2026-05-06 | $26.30M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $13.40M derived: sum of 2 quarters · filed 2026-02-25 | $19.80M derived: sum of 3 quarters · filed 2026-08-04 | $25.90M 10-K · filed 2026-02-25 |
| 2025-09-30 | $6.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.20M derived: sum of 2 quarters · filed 2026-08-04 | $19.30M 10-Q · filed 2025-11-05 | $25.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $12.50M 10-Q · filed 2026-08-04 | $18.70M derived: sum of 3 quarters · filed 2026-08-04 | $25.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $6.10M 10-Q · filed 2026-05-06 | $12.30M derived: sum of 2 quarters · filed 2026-05-06 | $18.80M derived: sum of 3 quarters · filed 2026-05-06 | $26.20M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.70M derived: sum of 2 quarters · filed 2026-02-25 | $20.10M derived: sum of 3 quarters · filed 2026-02-25 | $27.80M 10-K · filed 2026-02-25 |
| 2024-09-30 | $6.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.90M derived: sum of 2 quarters · filed 2025-11-05 | $21.60M 10-Q · filed 2025-11-05 | $29.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $7.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $15.10M 10-Q · filed 2025-08-06 | $22.60M derived: sum of 3 quarters · filed 2026-02-25 | $29.60M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $7.70M 10-Q · filed 2025-05-06 | $15.20M derived: sum of 2 quarters · filed 2026-02-25 | $22.20M derived: sum of 3 quarters · filed 2026-02-25 | $29.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $14.50M derived: sum of 2 quarters · filed 2026-02-25 | $21.40M derived: sum of 3 quarters · filed 2026-02-25 | $28.20M 10-K · filed 2026-02-25 |
| 2023-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $13.90M derived: sum of 2 quarters · filed 2024-11-06 | $20.70M 10-Q · filed 2024-11-06 | $27.30M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $6.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $13.70M 10-Q · filed 2024-07-31 | $20.30M derived: sum of 3 quarters · filed 2025-02-28 | $27.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $6.80M 10-Q · filed 2024-04-29 | $13.40M derived: sum of 2 quarters · filed 2025-02-28 | $20.10M derived: sum of 3 quarters · filed 2025-02-28 | $26.90M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $13.30M derived: sum of 2 quarters · filed 2025-02-28 | $20.10M derived: sum of 3 quarters · filed 2025-02-28 | $27.20M 10-K · filed 2025-02-28 |
| 2022-09-30 | $6.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-27 | $13.50M derived: sum of 2 quarters · filed 2023-10-27 | $20.60M 10-Q · filed 2023-10-27 | $27.70M derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-06-30 | $6.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $13.90M 10-Q · filed 2023-07-28 | $21.00M derived: sum of 3 quarters · filed 2024-02-12 | $28.10M derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-03-31 | $7.10M 10-Q · filed 2023-04-28 | $14.20M derived: sum of 2 quarters · filed 2024-02-12 | $21.30M derived: sum of 3 quarters · filed 2024-02-12 | $28.30M derived: sum of 4 quarters · filed 2024-02-12 |
| 2021-12-31 | $7.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-12 | $14.20M derived: sum of 2 quarters · filed 2024-02-12 | $21.20M derived: sum of 3 quarters · filed 2024-02-12 | $28.50M 10-K · filed 2024-02-12 |
| 2021-09-30 | $7.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $14.10M derived: sum of 2 quarters · filed 2022-10-28 | $21.40M 10-Q · filed 2022-10-28 | |
| 2021-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $14.30M 10-Q · filed 2022-07-29 | ||
| 2021-03-31 | $7.30M 10-Q · filed 2022-04-28 | |||
| 2020-12-31 | $28.20M 10-K · filed 2023-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |